Skip to main content

Table 1 Baseline characteristics by benign prostatic hyperplasia

From: Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan

Variables

BPH (−)

BPH (+)

P value

n

%

n

%

(Chi-square test)

n = 547584

465485

85.0

82099

15.0

 

Age (years)

     

  <40

28373

6.1

103

0.1

<0.0001

 40-49

88077

18.9

1692

2.1

 

 50-59

144677

31.1

11014

13.4

 

 60-69

106959

23.0

22785

27.8

 

 ≥70

97399

20.9

46505

56.7

 

Diabetes duration (years)

     

 <1

43069

9.3

1921

2.3

<0.0001

 1-3

83311

17.9

6379

7.8

 

 3-5

7748

16.7

9061

11.0

 

 ≥5

261623

56.2

64738

78.9

 

Nephropathy

53002

11.4

19913

24.3

<0.0001

Urinary tract diseases

59012

12.7

33818

41.2

<0.0001

Hypertension

248296

53.3

63518

77.4

<0.0001

Chronic obstructive pulmonary disease

60418

13.0

25837

31.5

<0.0001

Cerebrovascular disease

59318

12.7

23756

28.9

<0.0001

Ischemic heart disease

95649

20.6

33370

40.7

<0.0001

Peripheral arterial disease

52064

11.2

18708

22.8

<0.0001

Eye disease

75016

16.1

24855

30.3

<0.0001

Dyslipidemia

231613

49.8

42928

52.3

<0.0001

Heart failure

25584

5.5

11400

13.9

<0.0001

Obesity

6360

1.37

779

0.95

<0.0001

Alcohol-related diagnosis

14797

3.18

1885

2.30

<0.0001

Non-alcohol-related chronic liver disease

155679

33.44

30421

37.05

<0.0001

Rosiglitazone

64221

13.8

16898

20.6

<0.0001

Pioglitazone

22241

4.8

5191

6.3

<0.0001

Sulfonylurea

365375

78.5

74154

90.3

<0.0001

Meglitinide

51909

11.2

14783

18.0

<0.0001

Metformin

325652

70.0

69254

84.4

<0.0001

Acarbose

68578

14.7

18395

22.4

<0.0001

Insulin

68122

14.6

20951

25.5

<0.0001

Statin

133169

28.6

26302

32.0

<0.0001

Fibrate

106427

22.9

19705

24.0

<0.0001

Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

198383

42.6

52076

63.4

<0.0001

Calcium channel blocker

131769

28.3

40288

49.1

<0.0001

Non-steroidal anti-inflammatory drugs

303900

65.3

72262

88.0

<0.0001

Alpha-blockers

50456

10.84

69086

84.15

<0.0001

5-alpha reductase inhibitors

425

0.09

3409

4.15

<0.0001

Clopidogrel

14395

3.09

5346

6.51

<0.0001

Ticlopidine

11315

2.43

5278

6.43

<0.0001

Dipyridamole

78550

16.87

30566

37.23

<0.0001

Cyclophosphamide

456

0.10

147

0.18

<0.0001

Diuretics

103397

22.21

36462

44.41

<0.0001

Other cancer prior to baseline

41311

8.9

18433

22.5

<0.0001

  1. BPH benign prostatic hyperplasia.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us